These findings support future studies to evaluate the clinical potential of combinations of ROCK inhibitors with PEG-IFNα and/or the JAK inhibitor ruxolitinib33 for the treatment of MPN patients. The gene discussed is IFNA2; the disease is myeloproliferative neoplasm.